| Q50512619 | Acute massive gentamicin intoxication in a patient with end-stage renal disease. |
| Q48309663 | Aminoglycoside ototoxicity in pediatric patients receiving long-term peritoneal dialysis |
| Q38676819 | Aminoglycoside-induced hearing loss in humans |
| Q47211006 | Bayesian pharmacokinetics of gentamicin in a haemodialysis population |
| Q40730362 | Cost considerations in therapeutic drug monitoring of aminoglycosides |
| Q35117551 | Incidence of potentially toxic concentrations of gentamicin in the neonate |
| Q70239512 | Infection of the abdominal cavity and chronic peritoneal dialysis |
| Q50354695 | Preventing amikacin related ototoxicity with N-acetylcysteine in patients undergoing peritoneal dialysis. |
| Q28327774 | Relationship Between Aminoglycoside-Induced Nephrotoxicity and Auditory Toxicity |
| Q40196347 | Serum level monitoring of antibacterial drugs. A review |
| Q37268122 | The Incidence of Amikacin Ototoxicity in Multidrug-ResistantTuberculosis Patients |